SCHEMBL264016

SCHEMBL264016

CCOC(=O)c1occ(C)c1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.49
AHR P35869 1/20 0.49
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAOA P21397 1/20 0.44
ALDH1A1 P00352 9/20 0.42
HSD17B10 Q99714 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GAA P10253 5/20 0.42
HPGD P15428 5/20 0.42
MAPT P10636 5/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPK1 P28482 1/20 0.41
TSHR P16473 1/20 0.40
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12596492 0.81 KDM4E (0.46) KDM4EAHRLMNACYP1A2CYP3A4
SCHEMBL12559221 0.81 KDM4E (0.43) KDM4EAHRLMNACYP1A2CYP3A4
SCHEMBL19503203 0.80 TDP1 (0.49) KDM4ELMNACYP3A4ALDH1A1L3MBTL1
SCHEMBL4421367 0.78 KDM4E (0.43) KDM4EAHRLMNACYP1A2CYP3A4
SCHEMBL8066761 0.77 L3MBTL1 (0.44) KDM4EAHRLMNACYP1A2CYP3A4
SCHEMBL18233765 0.75 MAOB (0.41) KDM4EAHRALDH1A1L3MBTL1MAPT
SCHEMBL3936359 0.75 L3MBTL1 (0.39) KDM4EAHRLMNACYP1A2CYP3A4
SCHEMBL3068561 0.75 MAPT (0.48) KDM4EAHRLMNACYP1A2CYP3A4
SCHEMBL5548523 0.73 KDM4E (0.50) KDM4EAHRLMNACYP1A2CYP3A4
SCHEMBL14875594 0.72 GAA (0.40) KDM4EAHRLMNACYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163703-B2 Hepatitis C therapies BIOCRYST PHARMACEUTICALS, INC. (US) 2012-04-24 US disclosed
US-8133870-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2012-03-13 US disclosed
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 US disclosed
US-20100143300-A1 HEPATITIS C THERAPIES WILMINGTON TRUST, NATIONAL ASSOCIATION 2010-06-10 US disclosed
US-7514410-B2 Hepatitis C therapies BIOCRYST PHARMACEUTICALS, INC. (US) 2009-04-07 US disclosed
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-12-04 US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 US disclosed
US-7429571-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines DPYD, TYMP, TYMS KDM4E 1857/4885AHR 3770/4885LMNA 4216/4885
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof FEN1, UNG, POLH KDM4E 1575/4885AHR 3713/4885LMNA 2294/4885
US-20100143300-A1 HEPATITIS C THERAPIES HAVCR2, FABP1, LIPC KDM4E 4456/4885AHR 554/4885LMNA 2775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.